ScripNews that US Food and Drug Administration Center for Biologics Evaluation and Research (CBER) director Peter Marks submitted his resignation, effective 5 April, late in the day on 28 March shook the b
ScripThird Harmonic Bio and Q32 Bio are not in imminent danger of running out of cash, but both companies recently took a look at early data for their lead drug candidates and decided to significantly cut
ScripJanuary’s J.P. Morgan Healthcare Conference should set the tempo for biotech and pharma companies over the year as mergers and acquisitions along with early announcements of full-year 2024 financials
ScripIntellia Therapeutics, Inc.’s NTLA-2002 holds a strong position as it heads into Phase III development for hereditary angioedema (HAE), with Phase II data showing a high rate of functional cure. Howev